Dear Editor,

Since the end of 2019, the coronavirus disease 2019 (COVID-19) pandemic has struck worldwide, leading to more than 7 million cases by June 2020, with an approximately 5.5% mortality rate, mainly due to acute respiratory distress syndrome (ARDS) \[[@C1]\].

Current conventional treatment is mainly based on support therapy and there is an urgent need for effective, specific treatments.

Currently, no direct-acting antiviral drugs have demonstrated efficacy in the disease.

Contrariwise, increasing evidence indicates an immune-mediated pathophysiology that is paving the way for the evaluation of immunomodulation strategies \[[@C2]\].

Supporting this view, we would like to highlight the striking similarities between COVID-19 and a rare autoimmune disease: the anti-MDA5-syndrome.

The hallmark of this disease is the presence of auto-antibodies targeting MDA5, an intracellular sensor of viral RNA (including coronavirus) that triggers the innate immune response \[[@C3]\]. The syndrome is characterised by systemic signs resembling COVID-19, and ARDS is the main cause of death ([fig. 1a](#F1){ref-type="fig"}) \[[@C4], [@C5]\]. In addition, chest computed tomography findings \[[@C6]\], as well as blood cytokines profile \[[@C7], [@C8]\], are very similar in the two conditions ([fig. 1b](#F1){ref-type="fig"} and c) further supporting common pathophysiological mechanisms. There is, so far, no evidence that patients with COVID-19 have anti-MDA5 autoantibodies but, while other diseases causing ARDS feature "cytokine storm", few show such similarities with SARS-CoV-2 infection.

![Clinical and biological features of anti-MDA5 syndrome (a). Cytokines whose levels are increased in anti-MDA5 syndrome patients serum (b). High resolution computed tomography in an anti-MDA5 syndrome patient, showing bilateral peripheral subpleural ground glass opacities prevailing in the lower lobes (arrows), with limited consolidation (arrow head) (c). CK: creatine kinase. CRP: C-reactive protein. IFN-I: interferon type I. IL: interleukin. s-IL-2R: soluble interleukin-2 receptor. TNF-α: tumor necrosis factor α.](ERJ-01618-2020.01){#F1}

Beyond these similarities, anti-MDA5 syndrome responds to glucocorticoids and immunomodulatory drugs, among which tofacitinib (a JAK inhibitor) \[[@C9], [@C10]\] and a combination of tacrolimus and cyclophosphamide \[[@C11]\] have recently been shown to improve survival *versus* conventional strategies. Likewise, even though an immunological reaction is necessary to eliminate SARS-CoV2 infection and corticosteroids are currently not recommended by WHO \[[@C12]\], in severe COVID-19 patients, dexamethasone has just been reported to improve survival \[[@C13]\] and ruxolitinib (another JAK inhibitor) resulted in a greater chest tomography improvement and faster clinical improvement with no death compared to standard of care \[[@C14]\]. Moreover, tacrolimus has been shown to inhibit SARS-CoV replication \[[@C15]\].

These data support further evaluation of employing such an immunomodulatory strategy in COVID-19.
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